🔗 Share this article

A shadow market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, based on recent findings.

Investigational Treatment Gaining Popularity Via Social Media

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Viewers are urged to contact these accounts directly for supplier links, while also receiving promotional offers.

Active Trade on Social Networks

Additionally, a robust market exists on Telegram, where communities with thousands of participants share “before and after” images, injection guides and claims of rapid UK delivery. Vendors market the drug there before redirecting buyers to WhatsApp for transactions.

Learning About Retatrutide

Retatrutide is an investigational injection developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could help individuals reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Professionals Voice Concerns

However, doctors and pharmacists have warned that the distribution of what is still an unlicensed medication in the United Kingdom is worrisome and could result in individuals administering products of unknown origin.

Some experts said the demand for retatrutide could be linked to the rising cost of licensed slimming treatments such as Mounjaro.

Regulatory Status and Enforcement

Marketing the unapproved drug on social media or Telegram is illegal in the UK, as it is an unapproved drug that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but promotion and distribution can still breach medicines, advertising, and consumer regulations, potentially leading to fines, prosecution or imprisonment.

Platform Response and Material Elimination

According to TikTok, the platform has removed violative content and banned associated hashtags and search suggestions. The company said it was dedicated to keeping the service secure and allocating resources in strengthening compliance measures.

Digital Trading Activities

Research also discovered communities with up to nine thousand participants marketing the experimental drug using the platform's built-in discovery tool, which functions like a online catalog. Typing “retatrutide” instantly brings up groups with numerous of members, populated with images of weight loss, positive reviews and step-by-step instructions for mixing or administering at home.

After moments of entering one community, a seller shared contact information, where most transactions occur. The vendor provided an instruction manual and promised delivery within 48 hours. When asked whether the product was authentic, one seller said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. None asked about weight, health issues or past usage.

Item Details and Pricing

Inside these communities, posts show black plastic packages with postal service stickers, claiming to contain new batches. One message read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, prepared at residence with sterile water, or pre-filled injectors typically sold at £160 for 20 milligrams. When questioned how much time a injector should be used, vendors give conflicting answers ranging from a several days to “depends on your body”.

Platform Moderation and Security Actions

A spokesperson for the messaging service said it regularly monitored harmful content on its service including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“Individuals are administering materials they cannot confirm. Although the research behind retatrutide is sound, these digital versions may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the increase in demand to current price rises for approved slimming drugs such as Mounjaro. “With costs rising, individuals are using social media. But fake treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were made in was clean,” she said.

Her staff has previously encountered patients harmed by personal administration from unconfirmed suppliers. “We understand the frustration, but purchasing from messaging apps or WhatsApp is taking chances with your health,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a company investigational product not yet authorized … may expose users to potentially serious medical dangers”.